Comments
Shares of Cipla fell today after the company said that the US drug regulator had completed its inspection at Patalganga facility with 4 observations.
At 11.30 am, the stock was quoted loewr by 1.52% at Rs 445.90 on the BSE.
In a filing to the BSE, Cipla stateD: "We would like to inform you that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection for both Formulations and APis at our manufacturing facility in Patalganga from 4th November, 2019 to 13th November, 2019.
The inspection ended with 4 observations, none of which were repeat or related to data integrity. The Company is committed to addressing these observations and will submit i ts response to the agency within the stipulated time."
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.